CXCL8 and neoplasm: Knockdown of CXCL8 inhibited angiogenesis and tumor growth and CXCL8 might serve as a potential new biomarker and therapeutic target to overcome epidermal growth factor (EGRF)-tyrosine kinase inhibitor (KI) resistance in the future (Liu et al., 2023).